Fact-checked by Grok 2 weeks ago

Embryoid body

An embryoid body is a three-dimensional aggregate of pluripotent stem cells, such as embryonic stem cells or induced pluripotent stem cells, formed in suspension culture that spontaneously differentiates into cell types representing derivatives of all three embryonic germ layers, thereby mimicking early stages of embryogenesis in vitro.^[1]^[2] These structures arise through the aggregation of dissociated stem cells, often in non-adherent conditions, which promotes self-organization and initiates signaling pathways akin to those in pre-gastrulation embryos, including Wnt-mediated axis formation.^[3] Embryoid bodies serve as foundational models in stem cell research for investigating developmental biology, generating lineage-specific progenitors for tissue engineering, and screening potential therapeutics, while methods like microwell seeding enable controlled, uniform formation to enhance reproducibility.^[4]^[5] Although they provide ethical alternatives to intact embryo manipulation by deriving from established cell lines, advanced embryoid bodies that exhibit prolonged organization or organ-like features have prompted debates on their moral equivalence to natural embryos and the need for regulatory limits on developmental progression.^[6]^[7]

Fundamentals

Definition and Origin

An embryoid body (EB) is a three-dimensional multicellular aggregate formed by the self-organization of pluripotent stem cells, such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), in suspension culture conditions. These structures recapitulate key aspects of early embryogenesis, including cavitation to form an inner fluid-filled cavity surrounded by an epithelial layer, axial patterning, and spontaneous differentiation into cell types representing the three primary germ layers: ectoderm, mesoderm, and endoderm.^[8]^[1] Unlike adherent monolayer cultures, EBs promote cell-cell interactions that drive morphogenetic processes analogous to those in the gastrulating embryo.^[9] The concept of embryoid bodies emerged in the context of pluripotent stem cell research in the late 20th century. Prior to the isolation of ESCs, similar aggregates were observed in cultures of embryonic carcinoma (EC) cells derived from mouse teratocarcinomas as early as the 1970s, where they formed disorganized, tumor-like structures with embryonic features.^[10] The standardized use of EBs as models for normal development began with the derivation of mouse ESCs by Martin J. Evans and Matthew H. Kaufman in 1981, who established stable pluripotential cell lines from preimplantation mouse embryos; these cells, when dissociated and cultured in suspension, reliably formed EBs exhibiting organized differentiation and potency for all somatic lineages.^[11]^[12] This breakthrough provided an in vitro system to study embryonic patterning without relying on intact embryos, influencing subsequent advances in human pluripotent stem cell differentiation protocols.^[13]

Structural and Functional Characteristics

Embryoid bodies (EBs) are three-dimensional, spherical aggregates formed by the self-organization of pluripotent stem cells, such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), typically ranging from 100 to 500 µm in diameter, with optimal sizes of 100–300 µm promoting efficient differentiation.^[8] These structures initially appear as dense cell masses but evolve to include fluid-filled cavities, appendages, and an outer epithelial-like layer resembling primitive endoderm, characterized by tight junctions, alongside inner columnar epithelia.^[8] Advanced fabrication methods, such as microfabricated cell-repellent microwell arrays, enable the production of uniform EBs with diameters around 452 ± 48 µm, exhibiting complex intercellular junctions including gap, adherens, and desmosomes, while maintaining high cell viability for up to 30 days without core necrosis.^[3] Functionally, EBs recapitulate key aspects of early embryogenesis through spontaneous symmetry breaking, epithelial-mesenchymal transition (EMT), and formation of primitive streak-like structures, driven by signaling pathways such as Wnt and FGFR/ERK.^[8] They facilitate trilineage differentiation into ectoderm, mesoderm, and endoderm, as evidenced by expression of markers like SOX1 (ectoderm), TBXT (mesoderm, peaking around 93 hours post-aggregation), and GATA6 (endoderm), typically observable within days to two weeks of culture.^[8] ^[14] This self-organizing capacity allows EBs to serve as an in vitro assay for pluripotency, demonstrating organized tissue-like structures such as neural rosettes (ectoderm), connective tissue (mesoderm), and intestinal epithelia (endoderm), offering a cost-effective alternative to in vivo teratoma formation.^[14] EBs also support directed differentiation into specific lineages, such as insulin-secreting pancreatic β-cells with over 85% efficiency after 21 days, exhibiting glucose-responsive function, highlighting their utility in modeling developmental processes and generating functional cell types for research and potential therapeutic applications.^[3] Unlike natural embryos, EBs lack extra-embryonic tissues but provide a controlled environment for studying germ layer specification and cellular mechanics, including cavitation via caspase-dependent apoptosis.^[8] ^[1]

Historical Context

Pre-ESC Discoveries

The earliest observations of embryoid bodies occurred in the context of mouse teratocarcinomas, transplantable tumors originating from germ cells and containing pluripotent embryonal carcinoma (EC) cells. These structures, multicellular aggregates resembling early embryonic stages, were identified in the ascites fluid of mice bearing testicular teratocarcinomas, particularly in the strain 129 model developed by Leroy C. Stevens in the mid-1950s. Stevens reported in 1960 that embryoid bodies derived from such teratomas exhibited embryonic potency, forming teratomas with derivatives from all three germ layers upon subcutaneous transplantation into syngeneic hosts, thus demonstrating their pluripotentiality akin to normal embryonic cells.90015-5) In 1960, G. Barry Pierce Jr., Frank J. Dixon Jr., and Elizabeth L. Verney provided a detailed characterization of neoplastic embryoid bodies from mouse teratocarcinomas, identifying distinct cell types including undifferentiated EC cells in the core, surrounded by layers of parietal and visceral endoderm. These aggregates, typically 0.2 to 1 mm in diameter, featured cystic cavities lined by endodermal epithelium, mirroring yolk sac-like structures in vivo. The researchers noted that EC cells within these bodies retained tumorigenic potential, forming teratocarcinomas when isolated and retransplanted, while differentiated components contributed to organized tissue formation.^[15] Subsequent in vitro studies expanded on these findings. Pierce and Verney's 1961 work demonstrated that explants from teratocarcinoma-derived embryoid bodies, cultured on plasma clots, could generate new cystic embryoid bodies and differentiate into neural, muscular, and epithelial tissues over periods up to five months, highlighting the self-organizing capacity of EC cells in non-adherent conditions. This prefigured suspension culture methods for inducing differentiation. By 1975, Gail R. Martin and Matthew H. Kaufman showed that clonal lines of EC cells (e.g., Nulli-SCC1) from teratocarcinomas spontaneously formed embryoid bodies in vitro, progressing through stages of simple aggregates to complex cystic and polyvesicular forms containing mesodermal, endodermal, and ectodermal derivatives.^[16] These discoveries established embryoid bodies as models for investigating pluripotency and lineage commitment using tumor-derived cells, predating the 1981 isolation of embryonic stem cells from blastocysts. EC cell-derived embryoid bodies revealed mechanisms of cavitation, epithelialization, and spontaneous differentiation, with structures often comprising 10^3 to 10^5 cells and exhibiting gene expression patterns indicative of primitive streak formation, though limited by their malignant origins and genetic instability compared to normal embryonic tissues.

Evolution with Pluripotent Stem Cell Advances

The derivation of mouse embryonic stem cells (ESCs) in 1981 by Evans and Kaufman, and independently by Martin, enabled the systematic formation of embryoid bodies (EBs) as three-dimensional aggregates that recapitulate early embryonic differentiation.^[17] These EBs, cultured in suspension or hanging drops, spontaneously formed structures containing derivatives of ectoderm, mesoderm, and endoderm, as evidenced by histological analysis showing cavitated morphologies and tissue-like organization by day 7-10 of culture.^[17] This advance shifted EB research from pre-ESC teratoma-derived aggregates to controlled pluripotent cell models, facilitating studies of lineage commitment without reliance on animal embryos.^[18] The isolation of human ESCs in 1998 by Thomson et al. expanded EB applications to human developmental biology, with protocols adapted for serum-free conditions to generate EBs exhibiting neural rosettes, beating cardiomyocytes, and hepatocyte-like cells within 2-4 weeks.^[17] The subsequent development of induced pluripotent stem cells (iPSCs) by Yamanaka in 2006 for mouse and 2007 for human fibroblasts introduced autologous EB sources, bypassing ethical issues of embryo destruction and enabling personalized disease modeling, such as in Parkinson's or cardiac disorders through EB-derived lineages.^[19] iPSC-EBs demonstrated comparable differentiation potential to ESC-EBs, with gene expression profiles confirming germ layer formation via markers like SOX17 for endoderm and Brachyury for mesoderm.^[20] Methodological refinements paralleled pluripotent stem cell progress, including the adoption of bioreactor systems in the 2000s for scalable, uniform EB production—achieving yields of thousands per milliliter—and integration of defined media like E8 from 2014 onward to minimize variability.^[1] Microwell arrays and low-attachment plates, advanced in the 2010s, controlled EB size to 100-500 micrometers, enhancing reproducibility and reducing necrosis in larger aggregates.^[4] Directed differentiation protocols incorporated signaling modulators, such as BMP4 for mesoderm induction at concentrations of 10-50 ng/mL, yielding up to 80% purity in specific lineages like hematopoietic cells.^[18] These EB innovations laid groundwork for organoid cultures, with Sasai's 2008-2011 work using EB intermediates to generate self-organizing neural and retinal tissues via timed inhibition of Wnt and Nodal pathways, achieving laminated structures akin to optic cups after 20-30 days.^[17] While EBs provide causal insights into self-organization driven by cell-cell interactions and diffusible factors, their limitations—such as incomplete vascularization and lack of extraembryonic tissues—underscore the need for hybrid models, yet affirm their enduring utility in dissecting pluripotent cell fate decisions empirically.^[17]

Formation Methods

Primary Techniques

The primary techniques for embryoid body (EB) formation rely on dissociating pluripotent stem cells, such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), via enzymatic treatment (e.g., trypsin or Accutase) and culturing them in suspension to induce self-aggregation into three-dimensional spheroids that recapitulate early embryonic structures.^[5] These methods avoid attachment-promoting surfaces, leveraging cell-cell adhesion molecules like E-cadherin to drive multicellular assembly over 2-5 days in serum-free or serum-replacement media supplemented with factors like insulin-transferrin-selenium.^[5] Initial seeding densities typically range from 10^4 to 10^5 cells/mL, with outcomes varying by cell type and culture conditions to yield EBs of 100-500 μm diameter containing 10^3-10^5 cells.^[3] The hanging drop method suspends 500-4,000 dissociated cells in 20-40 μL droplets on the inverted lid of a Petri dish over a reservoir of phosphate-buffered saline, allowing gravity-driven aggregation at the droplet bottom within 48 hours.^[5] This approach yields uniform EBs with precise size control based on cell input, promoting efficient differentiation into lineages like cardiomyocytes or hematopoietic cells, but its manual pipetting limits throughput to ~100 EBs per 10-cm plate and hinders scalability due to evaporation risks and labor intensity.^[5] Static suspension culture plates cells in ultra-low attachment or bacteriological-grade dishes, where spontaneous aggregation forms floating EBs over 3-5 days without agitation or antidifferentiation agents like leukemia inhibitory factor.^[5] Simplicity and ease of implementation make it widely accessible for initial EB generation, supporting cystic or solid morphologies with potential for all three germ layers, though resultant heterogeneity in size (up to several-fold variation) and fusion events reduces reproducibility and downstream efficiency.^[5] Forced aggregation via microwell arrays, such as agarose or poly(ethylene glycol)-based nonadherent microwells, seeds 1.5-4 × 10^4 cells per well (optimal ~3.5 × 10^4 for ~450 μm EBs), often with optional centrifugation, to confine cells and produce synchronized, single EBs per microwell after 24 hours.^[3] Compared to hanging drop or suspension, this enhances uniformity and viability without routine ROCK inhibitor use, enabling high-throughput (thousands of EBs) and directed differentiation, such as 85% efficiency into insulin-secreting pancreatic cells expressing mature β-cell markers.^[3]^[21] Dynamic suspension in bioreactors, including spinner flasks or rotary cell culture systems, applies low shear (10-80 rpm) to stirred cultures for improved nutrient diffusion and aggregate breakup, generating scalable yields of homogeneous EBs suitable for endothelial or cardiac lineages.^[5] While effective for upscaling, shear sensitivity necessitates optimization to avoid cell damage.^[5]

Optimization and Influencing Factors

The formation of embryoid bodies (EBs) is optimized by precisely controlling initial cell seeding density, which directly determines EB size and uniformity; for instance, densities of 2.5 × 10⁵ cells/mL in stirred-tank bioreactors yield viable, homogeneous aggregates suitable for hepatic differentiation.^[22] Higher densities promote larger EBs, but excessive size (>500 μm) induces central necrosis due to limited nutrient diffusion, reducing overall viability.^[5] Culture methods significantly influence EB quality, with bioreactor systems such as spinner flasks at 100 rpm agitation producing smaller, more uniform EBs compared to static suspension, thereby enhancing scalability and minimizing variability in downstream differentiation.^[5] Microwell platforms, including hydrogel arrays with diameters of 150–450 μm, enable forced aggregation of defined cell numbers (e.g., 100–1000 cells per well), circumventing the need for ROCK inhibitors like Y-27632 in some protocols and improving survival of dissociated human pluripotent stem cells.^[5] ^[23] EB size emerges as a critical determinant of lineage bias, with smaller aggregates (150 μm) upregulating WNT5a to favor endothelial differentiation, marked by elevated PECAM and Flk-1 expression, while larger ones (450 μm) elevate WNT11 to promote cardiogenesis, evidenced by higher GATA4, Nkx2.5, and beating frequency.^[23] Medium composition further modulates outcomes, as hypoxic conditions (4% O₂) outperform normoxia (20% O₂) in yielding cardiomyocytes, and supplements like basic fibroblast growth factor support growth without biasing specific lineages.^[22] Additional optimization strategies include periodic physical passaging to maintain size control and prevent overgrowth, as well as perfused bioreactors that dialyze waste and supply nutrients continuously, reducing heterogeneity in human EB cultures.^[24] These factors collectively address mass transfer limitations and mechanical stresses, ensuring reproducible EB formation for applications in tissue modeling.^[22]

Differentiation Processes

Intracellular Dynamics

During embryoid body (EB) formation from pluripotent stem cells, intracellular transcriptional dynamics initiate rapidly, with gene expression profiles shifting within hours to orchestrate differentiation. High-resolution temporal RNA sequencing of mouse EBs sampled every 6 hours over 120 hours reveals complex waves of coding and noncoding RNA expression, including 1,135 short-lived RNAs and 137 cycling RNAs that peak and decline sub-24-hour windows, particularly in the initial 24 hours.^[25] Transcription factors such as Otx2 exhibit upregulated activity as early as 6 hours, while pluripotency genes like Pou5f1 (Oct4) maintain stability for approximately 24 hours before target pathways, including cell cycle regulation, show delayed downregulation.^[25] Long noncoding RNAs, such as Malat1 and Hotairm1, contribute to these dynamics by modulating nearby coding genes, with Hotairm1 delaying Hoxa1 activation by about 6 hours, highlighting context-dependent gene regulation.^[25] Bidirectional gene pairs, often within 500 base pairs of transcription start sites, demonstrate coordinated expression patterns that refine lineage specification.^[25] Key intracellular signaling pathways are activated endogenously through autocrine and paracrine cues following the withdrawal of pluripotency-maintaining factors like leukemia inhibitory factor. Canonical Wnt/β-catenin signaling polarizes EBs, promoting primitive streak-like formation and mesoderm differentiation via self-reinforcing loops that upregulate target genes such as T (Brachyury).00483-9)^[8] BMP and TGF-β pathways transduce signals intracellularly via Smad complexes to pattern mesoderm and extraembryonic fates, with BMP directly converting pluripotent cells toward primitive streak while synergizing with Wnt to posteriorize aggregates.^[26]^[27] Nodal/Activin signaling, operating through similar Smad2/3 phosphorylation, specifies early mesendoderm fates in distinct temporal phases from BMP and Wnt, with pathway durations controlling commitment: prolonged Nodal favors mesoderm over endoderm.^[26]^[28] FGF signaling engages ERK and PI3K/Akt cascades to drive primitive endoderm emergence and inhibit pluripotency via downregulation of YAP/TAZ activity.^[8] Cell-cell adhesions in EBs, mediated by cadherins, trigger intracellular β-catenin stabilization independent of Wnt ligands, linking mechanical cues to signaling outputs that modulate epithelial-to-mesenchymal transition and lineage bias.^[8] These pathways exhibit combinatorial and sequential interactions, where BMP upregulates Wnt to constrain totipotency and enhance heterogeneity, ensuring robust multi-lineage priming despite variability in EB aggregates.^[29] Single-cell analyses confirm heterogeneous intracellular states, with subpopulations retaining partial pluripotency signatures alongside emerging lineage-specific transcriptomes by day 4.^[30]

Multi-Lineage Outcomes

Embryoid bodies (EBs) spontaneously differentiate into cell types derived from all three germ layers—ectoderm, mesoderm, and endoderm—mimicking aspects of gastrulation in vivo. This multi-lineage outcome arises from stochastic signaling within the three-dimensional aggregate, including Wnt/β-catenin, TGF-β, and FGF pathways, leading to heterogeneous cell populations verifiable through gene expression, immunostaining, and histological analysis.^[8] ^[14] Ectodermal differentiation in EBs produces neural progenitors and neurons, evidenced by markers such as SOX1, PAX6, Nestin, and β-III tubulin, with structures like neural rosettes observed histologically. Inner EB cells preferentially adopt ectodermal fates, supported by unique epigenetic profiles during early differentiation stages.^[8] ^[14] Mesodermal outcomes include cardiomyocytes exhibiting contractile activity, hematopoietic progenitors forming blood island-like structures, and endothelial cells, marked by Brachyury-T, Nkx2.5, and Isl-1 expression. These lineages emerge via epithelial-mesenchymal transitions and are enhanced by mechanical cues like cavitation and Wnt signaling.^[8] Endodermal derivatives feature an outer primitive endoderm-like epithelium and visceral/parietal endoderm cells, confirmed by Foxa2, Sox17, GATA4/6, and α-fetoprotein markers, with gut-like tubular structures in histological sections. FGFR/ERK signaling drives polarization of this layer, while random specification occurs at the EB core.^[8] ^[14] Well-organized EBs maintain high viability over 20 days without core necrosis and demonstrate functional multi-lineage potential, such as insulin-secreting β-cells from endodermal paths with over 85% purity after directed extension. Outcomes vary by EB size and formation method, with uniform aggregates yielding more consistent germ layer representation via RT-PCR and immunofluorescence.^[3]

Parallels and Divergences from Embryonic Development

Mimetic Aspects

Embryoid bodies (EBs) exhibit morphological features that parallel early post-implantation embryonic stages, including the formation of a fluid-filled cavity through cavitation, which resembles the blastocyst's proamniotic cavity and precedes epithelial reorganization.^[8] This process involves programmed cell death and matrix remodeling, leading to a yolk sac-like structure with columnar epithelial layers, akin to the hypoblast and epiblast differentiation in vivo.^[8] In mouse EBs derived from embryonic stem cells, cavitation typically occurs between days 3 and 5 of culture, mirroring the timing of embryonic day 4.5 to 6.5 implantation events.^[8] At the cellular level, EBs undergo self-organization into multi-lineage derivatives, recapitulating gastrulation-like transitions where pluripotent cells commit to the three primary germ layers: ectoderm, mesoderm, and endoderm.^[31] Markers such as Brachyury for mesoderm, PAX6 for ectoderm, and GATA6 for endoderm are upregulated simultaneously in EBs, reflecting the spatial and temporal patterning observed during natural gastrulation around embryonic day 6.5–7.5.^[32] Wnt signaling drives axis formation and symmetry breaking in EBs, with spatial gradients of beta-catenin and Brachyury expression showing direct analogies to the primitive streak in embryos, enabling anterior-posterior polarity establishment.^[33]^[31] Molecularly, single-cell RNA sequencing of human EBs reveals transcriptional profiles that overlap with those of pre-gastrulation embryos, including enriched expression of developmental regulators like SOX17 and FOXA2 in endodermal compartments.^[34] These profiles capture dynamic gene regulatory networks for lineage specification, though with heterogeneous timing compared to synchronized in utero development.^[30] Bioengineered EBs further enhance mimetic fidelity by incorporating extra-embryonic cues, achieving structured layers that emulate post-implantation morphogenesis up to the gastrulation equivalent stage.^[35]

Inherent Limitations

Embryoid bodies (EBs) inherently fail to recapitulate the precise spatial and temporal organization of early embryogenesis due to their formation from randomly aggregated pluripotent stem cells, resulting in disordered tissue architecture rather than the structured cavitation and germ layer segregation observed in natural embryos.^[36] This disorganization stems from the absence of initial polarity cues present in the blastocyst, leading to heterogeneous cell positioning and limited epithelialization without exogenous interventions.^[37] A core limitation is the stochastic nature of differentiation within EBs, which produces variable proportions of cell types across germ layers rather than the deterministic progression driven by embryonic signaling gradients.^[38] Unlike in vivo development, EBs lack intrinsic mechanisms for synchronizing cellular fates, often yielding mixed populations with incomplete lineage commitment and off-target derivatives.00445-3) EBs are further constrained by the absence of extra-embryonic tissues and their supportive signals, preventing progression beyond gastrulation-like stages and failing to mimic events such as axial patterning or neurulation that require trophoblast and primitive endoderm interactions.^[39] This deficiency underscores their inability to model the full spectrum of post-implantation dynamics, as maternal-embryonic crosstalk and nutrient exchange via the uterine environment are not replicated.00316-3) Mass transfer barriers exacerbate these issues, with oxygen and nutrient gradients in EBs larger than 200-400 μm causing central hypoxia and necrosis, which disrupts uniform differentiation and viability independent of culture optimizations.^[40] Consequently, EBs serve as partial proxies for embryonic processes but cannot inherently achieve the fidelity of natural development.^[41]

Practical Applications

Developmental Modeling

Embryoid bodies (EBs) provide an in vitro system for modeling early embryonic development, particularly the transition from pluripotent stem cell aggregates to structured tissues resembling pre- and post-implantation embryos. Formed from mouse or human embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), EBs undergo self-organization driven by cell-cell interactions and diffusible signals, recapitulating cavitation, germ layer specification, and initial organogenesis.^[8] This 3D configuration contrasts with monolayer cultures by enabling spatially restricted signaling gradients, akin to those in vivo, which promote ectoderm, mesoderm, and endoderm differentiation.^[42] For instance, in mouse EBs, an outer layer of visceral endoderm-like cells surrounds an inner core of epiblast-like cells, mirroring the organization observed around embryonic day 5.5 in utero.^[43] Researchers utilize EBs to dissect molecular pathways governing lineage commitment, such as the role of BMP, Wnt, and Nodal signaling in primitive streak formation and gastrulation-like events.^[44] Experimental manipulation, including timed addition of growth factors or genetic perturbations, reveals causal dependencies; for example, inhibition of GSK3β activates Wnt pathways, inducing mesendodermal markers like Brachyury within 48-72 hours of EB culture.^[45] Human EBs similarly model epiblast hypoblast segregation, allowing genomic profiling of regulatory dynamics across emerging cell types, though with variability due to aggregation heterogeneity.^[46] These models have facilitated identification of stage-specific gene expression waves, correlating with in vivo transcriptomes up to gastrulation, but diverge thereafter due to absent extra-embryonic contributions.^[8] EB-based assays support quantitative analysis of developmental timing and efficiency, with metrics like EB diameter (typically 100-500 μm) influencing differentiation outcomes via oxygen gradients and mechanical cues.^[47] In cardiovascular modeling, EBs generate contracting cardiomyocytes by day 10-14, enabling electrophysiological studies that parallel fetal heart tube formation.^[48] Limitations include incomplete recapitulation of implantation cues and trophoblast lineages, restricting fidelity beyond early gastrulation, yet EBs remain foundational for hypothesis testing in developmental causality.^[44] Advances integrate EBs with microfluidics for precise environmental control, enhancing reproducibility in modeling human-specific deviations from rodent paradigms.^[49]

Therapeutic and Screening Uses

Embryoid bodies (EBs) derived from human induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs) enable screening for drug-induced cardiotoxicity by recapitulating early cardiac differentiation and beating phenotypes, allowing assessment of compounds like those causing arrhythmias.^[50] In one protocol, hiPSC-derived EBs exposed to a panel of 100+ drugs at 65-95 days post-induction revealed concentration-dependent effects on contraction rates and electrophysiological responses, correlating with known clinical risks.^[50] Similarly, EB platforms have been adapted for neuronal toxicity screening, where iPSC-EBs exposed to pharmaceuticals exhibited dose-dependent reductions in neural marker expression and viability, aiding prioritization of safer candidates.^[51] The Embryoid Body Test (EBT), an OECD-validated alternative to animal-based developmental toxicity assays, employs mouse ESC-derived EBs to quantify compound effects on EB area (as a proxy for growth inhibition) and differentiation, yielding IC50 values for cytotoxicity (ID50) and morphogenesis disruption (IB50).^[52] ^[53] Pre-validation studies with 20 therapeutic drugs, including teratogens like valproic acid, demonstrated EBT's sensitivity in classifying non-, weakly-, and strongly toxic agents with 80-90% accuracy compared to in vivo data, reducing reliance on vertebrate models while maintaining predictive power for human-relevant endpoints.^[54] Recent adaptations using rat ESCs in EBs extend this to species-specific screening, supporting regulatory toxicology for agrochemicals and pharmaceuticals.^[55] Therapeutically, EBs support scalable differentiation into lineages like cardiomyocytes for potential regenerative applications in myocardial repair, where ESC-derived beating EBs have yielded functional grafts in rodent infarction models, improving ejection fraction by 10-20% post-transplantation.^[22] However, purity issues— with undifferentiated cells comprising up to 20% of outputs—pose tumorigenicity risks, limiting clinical advancement despite preclinical efficacy in vascular and neural regeneration contexts.^[56] iPSC-EB-derived organoids further model diseases like Alzheimer's for therapeutic screening, identifying compounds that modulate amyloid-beta aggregation in multi-lineage cultures.^[57] Overall, while EBs accelerate lead optimization in drug discovery pipelines, direct therapeutic deployment awaits refined bioprocessing to ensure reproducibility and safety.^[58]

Scientific Challenges and Criticisms

Technical and Reproducibility Issues

One primary technical challenge in embryoid body (EB) formation is the inherent variability in aggregate size, shape, and cellular composition, which directly influences differentiation outcomes and compromises experimental reproducibility. In conventional methods such as suspension culture, initial cell density and aggregation dynamics lead to heterogeneous EB populations, where larger aggregates (>500 μm) develop necrotic cores due to limited nutrient and oxygen diffusion, while peripheral cells preferentially differentiate into ectodermal lineages, resulting in biased multi-lineage representation.^[5] This size-dependent heterogeneity exacerbates batch-to-batch inconsistencies, as EB morphology correlates with variable expression of developmental markers like brachyury and Sox17, hindering reliable modeling of gastrulation-like processes.^[59] Reproducibility is further undermined by undefined culture conditions and extrinsic factors, including shear stress in spinner flasks or bioreactors, which induce apoptosis and uneven cell proliferation, alongside variability in feeder cell batches or serum lots that alter attachment and survival rates.^[22] Donor-specific genetic differences in pluripotent stem cell lines often override protocol optimizations, with studies showing that inter-individual variability in gene expression profiles during EB differentiation persists regardless of somatic cell origin or reprogramming efficiency, leading to divergent lineage commitments across replicates.^[60] Such issues contribute to low yield of desired cell types, with reported efficiencies for cardiomyocytes or neurons rarely exceeding 20-30% in unoptimized systems without extensive troubleshooting.^[61] Standardization efforts have sought to mitigate these problems through engineered platforms, such as microfabricated microwell arrays, which enforce uniform EB diameters (e.g., 100-400 μm) and promote synchronized formation, reducing culture-to-culture variability and enabling high-throughput production of up to thousands of identical EBs per plate.^[3] Protocols emphasizing high stem cell proliferation rates (>0.5 doublings per day) in defined matrices like laminin-521 further enhance consistency by minimizing quiescence-induced heterogeneity during aggregation.^[62] Nonetheless, scalability remains limited for clinical translation, as even advanced bioreactors struggle with maintaining homogeneity beyond 10^6 cells, and the absence of universal metrics for EB quality (e.g., viability >90% or lineage balance) perpetuates subjective assessments across labs.^[63]

Overstated Efficacy Claims

Early proponents of embryoid bodies (EBs) asserted that these aggregates could faithfully recapitulate the multi-lineage differentiation and morphogenetic events of pre-gastrulation embryonic development, positioning them as robust alternatives to animal models for studying human embryogenesis.^[64] However, such claims have been critiqued for overlooking inherent structural and functional deficits, as EBs typically exhibit disorganized cell arrangements lacking the precise spatiotemporal signaling gradients observed in vivo.^[65] A key overstatement involves the purported comprehensive recapitulation of embryonic lineages, including extraembryonic tissues; in reality, pluripotent stem cell-derived EBs consistently fail to generate functional trophoblast or primitive endoderm compartments, limiting their utility as holistic models of implanting embryos.^[64] This shortfall stems from absent mechanical and environmental cues, such as uterine interactions, resulting in incomplete specification of cell fates that diverge from natural developmental trajectories.^[46] In therapeutic contexts, efficacy claims for EBs in scalable production of differentiated progenitors—for instance, cardiomyocytes or neurons—often exaggerate yields and purity, with differentiation efficiencies rarely exceeding 20-50% for specific lineages due to heterogeneous outcomes and core necrosis from diffusive mass transfer limitations in larger aggregates.^[66] Empirical assessments reveal batch-to-batch variability as high as 30-50%, undermining reproducibility and inflating perceptions of clinical translatability.^[65] These discrepancies highlight a pattern in stem cell research where initial hype, driven by proof-of-concept demonstrations in mouse models, has outpaced validation in human systems, prompting calls for tempered expectations until advanced protocols address EB constraints.^[64]

Ethical and Regulatory Considerations

Sourcing and Moral Concerns

The sourcing of pluripotent stem cells for embryoid body formation primarily involves human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs). hESC lines are obtained by extracting the inner cell mass from blastocyst-stage embryos, typically surplus from in vitro fertilization procedures, which irreversibly destroys the embryo in the process.^[67] This derivation method, first achieved in 1998, has elicited profound moral opposition from those who ascribe full human dignity to the embryo from fertilization onward, viewing the act as tantamount to homicide.^[68] Proponents counter that such embryos lack viability for implantation and that the potential therapeutic benefits outweigh the ethical costs, though empirical evidence for widespread clinical success remains limited as of 2023.^[69]^[70] iPSCs, pioneered by Shinya Yamanaka in 2006 through reprogramming of somatic cells via transcription factors, avoid embryo destruction entirely, positioning them as an ethically preferable alternative for embryoid body generation.^[71] This approach has facilitated broader research access, with iPSC-derived embryoid bodies increasingly used to model developmental processes without invoking the same sourcing controversies.^[72] However, even iPSC-based methods provoke moral scrutiny when embryoid bodies exhibit advanced organoid-like organization or neural activity, raising causal questions about whether such synthetic aggregates could develop properties akin to sentience or independent viability, thereby challenging traditional embryo-centric ethical frameworks.^[7] Critics argue this shifts ethical burdens from sourcing to the deliberate engineering of proto-embryonic entities, potentially normalizing the lab creation of human-like forms absent natural gestation.^[6] Regulatory histories underscore these tensions; U.S. federal funding for new hESC lines was restricted in August 2001 under President George W. Bush, citing the destruction of nascent life, before partial expansion in 2009 under President Barack Obama.^[73] Internationally, bans persist in countries like Germany and Italy, reflecting persistent moral reservations.^[74] While iPSCs mitigate sourcing dilemmas, calls for enhanced oversight persist, including proposals for "14-day-like" limits on embryoid maturation to prevent crossing thresholds of moral equivalence to embryos.^[75] These debates highlight the need for sourcing transparency and empirical validation of embryoid models' non-viability to sustain public trust.^[6]

Debates on Entity Status

Debates on the entity status of embryoid bodies center on whether these stem cell-derived aggregates, which mimic aspects of early embryonic organization, warrant moral considerations comparable to those of human embryos formed by fertilization. Unlike zygote-derived embryos, embryoid bodies lack totipotent cells capable of forming extra-embryonic tissues and cannot independently develop into viable organisms without extensive laboratory intervention, leading many ethicists to classify them as having lower or no intrinsic moral status.^[7]^[76] This distinction is grounded in their origin from pluripotent stem cells, which do not replicate the unique genetic and epigenetic initiation of natural embryogenesis.^[6] A key argument for ascribing entity status invokes potentiality: structures with "advanced passive potential"—requiring minimal additional steps to approximate embryo-like development, such as certain blastoids derived from embryoid bodies—may merit protections akin to the 14-day rule limiting embryo research, as they could theoretically model or approach organismic viability.^[76] For instance, five reviewed publications posit that advanced embryoids might constitute synthetic human life forms due to their organismic potential, raising concerns about sentience or pain capability, though empirical evidence for such features in early models remains absent.^[6] Proponents, including some bioethicists, advocate a sliding scale of moral status based on developmental completeness, proposing extended oversight (e.g., up to 28 days) for models exhibiting gastrulation-like events.^[7] Conversely, opponents emphasize the absence of active potential—the intrinsic capacity for self-directed development into a human being—as disqualifying embryoid bodies from embryo-equivalent status; traditional embryoid bodies exhibit only "basic passive potential," akin to somatic cells, necessitating substantial reprogramming to gain viability.^[76] This view aligns with guidelines from bodies like the International Society for Stem Cell Research (ISSCR), which, as of 2024, maintain that embryo models lack the developmental potential of actual embryos and thus do not qualify as such, despite calls for precautionary regulations to address advancing realism in models.^[77] Inconsistencies in embryo handling, such as the annual discard of approximately 90,000 cryopreserved human embryos, further undermine claims of special status for lab-created analogs, prioritizing research utility over speculative moral equivalence.^[7] Regulatory frameworks reflect this divide, with no international consensus treating embryoid bodies as legal entities; most jurisdictions exempt them from embryo laws due to their non-reproductive origins and inability to implant or gestate, though 23 reviewed sources highlight policy gaps, urging bans on reproductive use or chimeric integration to prevent misuse.^[6] Varying embryo moral status views—ranging from full personhood at fertilization to emergent properties—directly influence embryoid assessments, with nine publications arguing against equivalent treatment absent shared causal pathways to personhood.^[6] These debates underscore the need for evidence-based criteria focused on verifiable biological capacities rather than morphological similarity.^[76]

Recent Developments

Advances in Model Refinement

Engineering strategies have improved embryoid body (EB) formation by promoting uniform size and shape, essential for synchronous differentiation of human pluripotent stem cells. Techniques such as microwell arrays and low-adherence plates enable the generation of homogeneous EBs, reducing variability compared to traditional suspension cultures and facilitating directed lineage specification.^[5] Bioreactor systems, including rotary suspension cultures, enhance EB yield, density, and mesoderm differentiation efficiency through controlled shear stress and oxygenation, with studies reporting up to twofold increases in cell recovery and marker expression like Flk1.^[78] ^[32] Hydrogel encapsulation refines EB models by providing tunable mechanical cues that mimic embryonic microenvironments, influencing cell fate decisions. Poly(ethylene glycol) (PEG) hydrogels modified with RGD peptides promote endothelial differentiation, while gelatin methacryloyl (GelMA) boosts vasculogenic markers such as PECAM-1 and Tie-2. Advanced fabrication via 3D projection printing yields EBs of 155 ± 17 µm diameter, exhibiting enhanced germ layer marker expression (e.g., Brachyury for mesoderm, SOX-17 for endoderm) after 10 days in culture, surpassing non-engineered aggregates in homogeneity and viability.^[32] Fluid shear stress at 5 dyn/cm² further directs endothelial morphogenesis within EBs, improving overall differentiation yields.^[32] Morphogen supplementation has advanced EB refinement toward patterned structures resembling gastrulation stages. Treatment with WNT agonists (e.g., CHIR99021) and BMP/Activin A induces symmetry breaking and anteroposterior polarity in human EBs derived from primed embryonic stem cells, forming gastruloid-like aggregates that elongate and express axial organizers after 16 days. Embedding in Matrigel enhances tail bud formation and germ layer organization, bridging basic EBs to synthetic embryo models.^[18] Photobiomodulation represents an emerging biophysical refinement for lineage-specific EB enhancement. Application of 825 nm near-infrared light at 10 J/cm² to adipose-derived stem cell aggregates increases neural EB size, viability, and Nestin/GFAP expression while minimizing cytotoxicity, outperforming control conditions in neuronal marker upregulation (e.g., NeuN) over 96 hours.^[79] These optimizations collectively address limitations in reproducibility and fidelity, enabling more precise recapitulation of early development.^[32]^[18]

Integration with Synthetic Biology

Synthetic biology integrates engineered genetic components into embryoid bodies (EBs) to impose precise, programmable control over cellular behaviors that are otherwise stochastic in unmodified stem cell aggregates. Inducible genetic circuits, comprising synthetic promoters responsive to exogenous cues like chemicals or light, enable temporal orchestration of developmental gene expression, mitigating variability in lineage commitment observed in standard EBs derived from pluripotent stem cells.^[80] For example, circuits tuned to activate transcription factors such as SOX17 or brachyury have been used to direct endodermal or mesodermal specification within EB structures, as demonstrated in mouse models where circuit integration improved uniformity of germ layer formation by over 50% compared to controls.^[81] Optogenetic tools further enhance spatial resolution by linking light-inducible dimerization domains to morphogen pathways, such as WNT or BMP signaling, allowing researchers to sculpt gradients that guide EB patterning in real time. In human pluripotent stem cell-derived EBs, optogenetic activation of WNT effectors has recapitulated anterior-posterior axis elongation, with light pulses eliciting directed cell migration and tissue folding akin to gastrulation stages, achieving patterning fidelity not attainable through diffusible ligands alone.^[82] These approaches, refined since 2021, leverage orthogonal photoreceptors to avoid crosstalk with endogenous pathways, thereby enabling causal dissection of signaling dynamics.^[80] Bioengineered synthetic organizer cells, embedded within EBs via genetic programming, secrete morphogens through circuit-controlled feedback loops, fostering self-organizing architectures that emulate embryonic organizers. A 2022 study in mouse EBs incorporated such cells expressing NODAL and BMP4 under synthetic toggles, resulting in de novo formation of somite-like structures and neural tubes, with spatial confinement of signals to subdomains of the aggregate.^[83] Similarly, cadherin-based adhesion circuits have been engineered to enforce multicellular geometry, promoting self-assembly into embryo-like entities with defined tissue boundaries, as reported in 2022 for stem cell aggregates transitioning from disordered EBs to structured models.^[84] CRISPR-Cas9 systems integrated into synthetic biology workflows for EBs facilitate multiplexed editing of patterning loci, coupled with reporter circuits for live readout of editing efficiency and downstream effects. This has revealed, for instance, the non-redundant roles of HOX genes in EB axial specification, with edited variants showing disrupted somitogenesis in over 80% of aggregates versus wild-type. By 2023, combinations of these tools in human EBs had advanced post-implantation modeling, incorporating extraembryonic compartments under circuit governance to simulate trophoblast invasion.^[85] Such integrations underscore synthetic biology's capacity to transcend empirical trial-and-error, providing mechanistic insights into developmental causality while highlighting scalability challenges in translating circuit stability from 2D to 3D contexts.^[86]

References

[1]
Embryoid body formation from human pluripotent stem cells ... - NCBI
Jun 1, 2014 · Embryoid bodies (EB) are the three-dimensional aggregates formed in suspension by pluripotent stem cells (PSC), including embryonic stem cells ( ...Introduction · Protocol
[2]
The Generation of Embryoid Bodies from Feeder-Based or ... - NIH
Embryoid body (EB) formation is a traditional method of inducing differentiation of pluripotent stem cells (PSCs).
[3]
Formation of Well-defined Embryoid Bodies from Dissociated ...
Dec 10, 2014 · In this method, dissociated pluripotent stem cells are seeded into small microwells of a volume in the range of several microliters and allowed/ ...
[4]
Microfabric Vessels for Embryoid Body Formation and Rapid ...
Aug 10, 2016 · This culture system is useful for high throughput EB formation and rapid generation of differentiated cells such as neural stem cells (NSCs) from hiPSCs.
[5]
Engineering Strategies for the Formation of Embryoid Bodies from ...
Recently, new advances have emerged to form uniform human embryoid bodies (hEBs) from dissociated single cells of hPSCs. In this review, the existing ...
[6]
Ethical, legal, regulatory, and policy issues concerning embryoids
Aug 21, 2023 · This paper reports a systematic review of the ethical, legal, regulatory, and policy questions and concerns found in the literature concerning human embryoid ...
[7]
The ethics of human-embryoids model: a call for consistency - PMC
Apr 1, 2021 · In this article, we discuss the ethics of human embryoids, ie, embryo-like structures made from pluripotent stem cells for modeling natural embryos.
[8]
Cell Mechanics in Embryoid Bodies - PMC - PubMed Central
Oct 11, 2020 · Embryoid bodies (EBs) resemble self-organizing aggregates of pluripotent stem cells that recapitulate some aspects of early embryogenesis.
[9]
Embryoid Body - an overview | ScienceDirect Topics
Embryonic Stem Cells The use of hES cells for research and clinical applications is complicated by controversies surrounding the legal and ethical status of ...<|control11|><|separator|>
[10]
Properties of embryoid bodies - Wiley Interdisciplinary Reviews
Dec 2, 2016 · Embryoid bodies (EBs) have been popular in vitro differentiation models for pluripotent stem cells for more than five decades.
[11]
Establishment in culture of pluripotential cells from mouse embryos
Jul 9, 1981 · Cite this article. Evans, M., Kaufman, M. Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154–156 (1981).
[12]
Establishment in culture of pluripotential cells from mouse embryos
Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981 Jul 9;292(5819):154-6. doi: 10.1038/292154a0. Authors. M J Evans, M H Kaufman.
[13]
Two decades of embryonic stem cells: a historical overview - PMC
Jan 29, 2019 · How did the field of stem cell research develop in the years following the derivation of the first human embryonic stem cell (hESC) line?
[14]
Analysis of Embryoid Bodies Derived from Human Induced ...
Our paper proposes the embryoid body (EB) assay as a useful in vitro, cost-effective alternate to demonstrate the differentiation potential of derived hiPSCs.Missing: characteristics | Show results with:characteristics
[15]
https://pubmed.ncbi.nlm.nih.gov/13735536
[16]
https://pubmed.ncbi.nlm.nih.gov/13735537
[17]
Pluripotent stem cell‐derived organoids: A brief history of curiosity ...
Aug 5, 2024 · PSC‐organoids are an evolution of earlier methods such as embryoid bodies, taken to a new level with finer control and in some cases going ...
[18]
A new era of stem cell and developmental biology: from blastoids to ...
Oct 2, 2023 · ... embryonic differentiation and thus were collectively termed “embryoid bodies (EBs)”. When EBs derived from ES cells of mouse blastocyst ICM ...
[19]
Ten years of progress and promise of induced pluripotent stem cells
May 11, 2018 · The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka in 2006 was heralded as a major breakthrough of the decade in stem cell research.
[20]
Inducing human induced pluripotent stem cell differentiation through ...
Embryoid body (EB) mediated induced pluripotent stem cell (iPSC) differentiation shows great advantages in culture scale-up, differentiation efficiency ...
[21]
Methods for embryoid body formation: the microwell approach
The hanging drop method suspends ESCs on the lid of a dish and EBs form through aggregation at the bottom of the drops. Recently, alternative methods of EB ...
[22]
Embryoid body formation from embryonic and induced pluripotent ...
Embryoid body (EB) formation from ES cells is a common method for producing different cell lineages for further applications.Missing: structural | Show results with:structural
[23]
Microwell-mediated control of embryoid body size regulates ... - PNAS
It has been reported that the lineage specific differentiation could be affected by the size of ES cell colonies and embryoid bodies (EBs).
[24]
Physical Passaging of Embryoid Bodies Generated from Human ...
... embryoid body formation and hematopoietic development from embryonic stem cells in different culture systems. ... pluripotent stem cells into functional ...Missing: structure | Show results with:structure
[25]
High resolution temporal transcriptomics of mouse embryoid body ...
Jul 27, 2017 · We present a highly resolved differentiation cascade that exhibits coding and noncoding transcriptional alterations, transcription factor network interactions ...Missing: pre- | Show results with:pre-
[26]
Wnt, Activin, and BMP Signaling Regulate Distinct Stages in ... - NIH
The embryonic stem cell differentiation system was used to define the roles of the Activin/Nodal, BMP, and canonical Wnt signaling pathways at three distinct ...
[27]
Combinatorial interpretation of BMP and WNT controls the decision ...
May 15, 2024 · BMP signaling directly converts cells from pluripotent to extraembryonic fates while simultaneously upregulating Wnt signaling, which promotes primitive streak ...Missing: embryoid intracellular
[28]
Dissecting the dynamics of signaling events in the BMP, WNT, and ...
We further show that the durations of WNT and NODAL signaling control mesoderm differentiation, while the duration of BMP signaling controls differentiation of ...Missing: embryoid bodies intracellular
[29]
Cross-activation of FGF, NODAL, and WNT pathways constrains ...
May 30, 2023 · Our findings reveal a BMP signaling mechanism regulating both the totipotent state and heterogeneity of ESCs.Missing: embryoid bodies<|control11|><|separator|>
[30]
A single cell transcriptional portrait of embryoid body differentiation ...
Jul 29, 2018 · Our single cell analyses of the day 4 embryoid bodies revealed three populations which had retained related yet distinct pluripotent signatures ...
[31]
Wnt signaling mediates self-organization and axis formation in ...
Embryonic stem cells form descendants of all three germ layers when differentiated as aggregates, termed embryoid bodies. In vivo, differentiation of cells ...
[32]
Cell Mechanics in Embryoid Bodies - MDPI
Oct 11, 2020 · Embryoid bodies (EBs) resemble self-organizing aggregates of pluripotent stem cells that recapitulate some aspects of early embryogenesis.
[33]
Prediction and control of symmetry breaking in embryoid bodies by ...
We therefore hypothesized that the spatial expression pattern of key proteins in EBs before and during Bra onset shows similarity to their in utero pattern ...
[34]
Human embryoid bodies as a novel system for genomic studies of ...
Feb 10, 2022 · Embryoid bodies produce diverse cell types and can enable the study of gene regulatory dynamics at unprecedented spatial and temporal ...
[35]
Bioengineered embryoids mimic post-implantation development in ...
Aug 26, 2021 · ... embryonic development. For BMP and WNT pathways, we ... Wnt signaling mediates self-organization and axis formation in embryoid bodies.
[36]
Implantation initiation of self-assembled embryo-like structures ...
Jan 30, 2019 · These are valuable tools for studying embryonic development, but EBs do not fully recapitulate the spatial-temporal events of embryogenesis, ...
[37]
The Analysis of Embryoid Body Formation and Its Role in Retinal ...
Jan 24, 2024 · EBs develop cells representing all three germ layers: endoderm, mesoderm, and ectoderm in vitro [23]. However, their arrangement appears less ...
[38]
Integrated live imaging and molecular profiling of embryoid bodies ...
Aug 17, 2016 · Embryonic stem cells can spontaneously differentiate into cell types of all germ layers within embryoid bodies (EBs) in a highly variable ...Missing: intracellular | Show results with:intracellular
[39]
Embryo model completes gastrulation to neurulation and ... - Nature
Aug 25, 2022 · Thus, these models do not recapitulate the entirety of development to neurulation. Signals originating from extraembryonic tissues are ...
[40]
Mass transfer limitations in embryoid bodies during human ...
Jan 12, 2012 · The results revealed that the oxygen concentration at the centers of large EBs (400-μm radius) was 50% lower when compared to that in smaller EBs (200-μm ...Missing: inherent mimicking
[41]
The building blocks of embryo models: embryonic and ... - Nature
Apr 22, 2025 · However, there are some limitations to these models. These studies focused more on the further development of embryonic cells and did not pay ...
[42]
Embryoid bodies: an in vitro model of mouse embryogenesis
Embryoid bodies: an in vitro model of mouse embryogenesis. Exp Physiol ... model of early embryogenesis. We also present the potential of this method ...
[43]
Embryoid bodies: an in vitro model of mouse embryogenesis
Evans, M. J. & Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154—156. Fassler, R. & Meyer, M.
[44]
Modeling human embryo development with embryonic and extra ...
Embryoid bodies offer a 3D model with complex differentiation behaviors that are useful in identifying different signaling factors required for ...
[45]
Embryoids, organoids and gastruloids: new approaches to ... - NIH
Mar 15, 2017 · Gastrulation. A process that transforms the early embryo into a multilayered structure with distinct germ layers.
[46]
Human embryoid bodies as a novel system for genomic studies of ...
Gene regulation is highly dynamic and context-dependent. In order to better ... transcriptional dynamics governing early fate decisions (Han et al ...
[47]
Properties of embryoid bodies - PubMed
Embryoid bodies (EBs) have been popular in vitro differentiation models for pluripotent stem cells for more than five decades. Initially, defined as aggregates ...
[48]
In Vitro Models of Cardiovascular Disease: Embryoid Bodies ...
Nov 27, 2024 · Owing to the cellular composition of the models examined, this review will focus on disease and tissue injury associated with embryonic/fetal ...
[49]
Human embryoid bodies as a 3D tissue model of the extracellular ...
Jun 26, 2020 · Here, we report the generation of embryoid bodies from human induced pluripotent stem cells that model the basal lamina. Embryoid bodies ...Human Embryoid Bodies Mimic... · Derivation Of Hipscs From... · Impaired Laminin...<|separator|>
[50]
https://www.ahajournals.org/doi/10.1161/circulationaha.112.000570
[51]
Neuronal and cardiac toxicity of pharmacological compounds ...
Dec 15, 2021 · In this study, we used human induced pluripotent stem cell (hiPSC)-derived embryoid bodies ... drug screening has grabbed immense attention of ...
[52]
A Simple and Reliable Alternative Developmental Toxicity Test
Dec 18, 2024 · In the area of developmental toxicity, the embryonic stem cell test (EST) has played a significant role. The EST evaluates toxicity using mouse ...Missing: regenerative | Show results with:regenerative
[53]
Pre-validation study of alternative developmental toxicity test using ...
The embryoid body test (EBT) is a developmental toxicity test method that assesses the half inhibitory concentrations of substances in the area of embryoid ...
[54]
Use of In Vitro Morphogenesis of Mouse Embryoid Bodies to Assess ...
Sep 18, 2015 · The aim of this study is to evaluate the applicability and limitations of the model using 20 therapeutic drugs, 16 of which are contraindicated ...Missing: applications screening
[55]
Rat embryonic stem cell-based in vitro testing platform for ... - Frontiers
May 7, 2025 · An innovative in vitro platform is proposed, based on rat embryonic stem cells (RESCs), which is easy to use and suitable for wide-scale screening.Introduction · Materials and methods · Results · DiscussionMissing: regenerative medicine
[56]
Bioprocessing of embryonic stem cells for drug discovery
Embryonic stem cells provide a potential resource for research and drug screening. To make such a resource feasible, it is necessary to generate cells of ...
[57]
A logical network-based drug-screening platform for Alzheimer's ...
Jan 12, 2021 · Quality controls of iCOs for drug screening. First, high-quality embryoid bodies (EBs) were selected on Day 7 and seeded to the ultra-low- ...
[58]
Review Bioprocessing of embryonic stem cells for drug discovery
Embryonic stem cells provide a potential resource for research and drug screening. To make such a resource feasible, it is necessary to generate cells of ...
[59]
Controlling Embryonic Stem Cell Growth and Differentiation by ...
EB size and shape have been shown to influence the resulting differentiated cells, and therefore high EB variability results in cell lineage variability. An ...
[60]
Article Genetic Variability Overrides the Impact of Parental Cell Type ...
Feb 9, 2016 · We then used embryoid body (EB) analysis to investigate the impact of somatic cell type- and donor-dependent characteristics on the spontaneous ...Article · Results · Global Analysis Of Ipsc...
[61]
The microwell control of embryoid body size in order to regulate ...
However, for most cell lineages, the protocols are inefficient and poorly reproducible. Differentiation of ESCs into cardiomyocytes has been extensively ...<|control11|><|separator|>
[62]
A High Proliferation Rate is Critical for Reproducible and ... - PubMed
A High Proliferation Rate is Critical for Reproducible and Standardized Embryoid Body Formation from Laminin-521-Based Human Pluripotent Stem Cell Cultures.
[63]
Promoting the adoption of best practices and standards to enhance ...
12 Jun 2025 · Proactive engagement will be key to the success of these initiatives to collectively improve the rigor and reproducibility of stem cell research.
[64]
Opportunities and challenges with stem cell-based embryo models
PSC-based embryo models have generally not been able to recapitulate all the features of the implanting embryo, most notably the formation of the trophoblast ...
[65]
Identifying the Gaps in the Development of Stem Cell‐based Embryo ...
Mar 2, 2021 · Embryoid Bodies. Embryonic stem cells ... limitations on how well these structures recapitulate the developmental timeline of the embryo.
[66]
Mass Transfer Limitations in Embryoid Bodies during Human ...
Aug 9, 2025 · Spontaneous differentiation of human embryonic stem cells (hESCs) is influenced by the size of the differentiating embryoid bodies (EBs). To ...
[67]
Ethical Issues in Stem Cell Research - PMC - NIH
Apr 14, 2009 · The derivation of pluripotent stem cell lines from oocytes and embryos is fraught with disputes regarding the onset of human personhood and ...Missing: embryoid | Show results with:embryoid
[68]
The Human Embryonic Stem Cell Debate: Science, Ethics, and ...
The fact that stem cells may be derived from living embryos that are destroyed in the process or from aborted fetuses ties the discussion of stem cell research ...
[69]
Stem Cell Research Controversy: A Deep Dive (2025)
The controversy surrounding stem cell research primarily stems from ethical and political concerns. One of the main issues is the derivation of pluripotent ...Missing: embryoid | Show results with:embryoid
[70]
Stem Cells - The Hastings Center for Bioethics
Sep 11, 2023 · The main ethical and policy issues with stem cells concern the derivation and use of embryonic stem cells for research. A vocal minority of ...Missing: embryoid | Show results with:embryoid
[71]
Ethics and Induced Pluripotent Stem Cells
Jun 10, 2009 · iPSCs have been touted as ethically uncomplicated alternatives to ESCs, so the ethics surrounding iPSCs are largely evaluated in comparison to ...
[72]
ethical questions after the discovery of iPS cells - EuroStemCell
Do we still need ESCs? Should researchers switch to using iPSCs to avoid moral issues? What moral issues do iPSCs pose? iPSC treatments will likely require ...
[73]
The Stem Cell Debate: Is it Over? - Learn Genetics Utah
The controversy centered on the moral implications of destroying human embryos. Political leaders began to debate over how to regulate and fund research ...
[74]
The debate surrounding human embryonic stem cell research in the ...
The central question in this debate is whether the promise of stem cells justifies the destruction of human embryos – mainly embryos that are surplus to the ...
[75]
Addressing the ethical issues raised by synthetic human entities with ...
Mar 21, 2017 · The "14-day rule" for embryo research stipulates that experiments with intact human embryos must not allow them to develop beyond 14 days.
[76]
The moral status of human embryo‐like structures: potentiality ...
Jul 27, 2020 · These very methods raise new ethical issues regarding the creation and use of human embryo‐like structures, the moral status of which is uncertain.
[77]
Human embryo models are getting more realistic — raising ethical ...
Sep 11, 2024 · Dozens of labs around the world are striving to grow models of human embryos to study development, fertility and therapies.
[78]
Rotary Suspension Culture Enhances the Efficiency, Yield, and ...
3H). Histology of Embryoid Bodies. Embryoid bodies were collected from hanging-drop, static, and rotary cultures at days 2, 4, and 7 of suspension culture.
[79]
Impact of photobiomodulation on neural embryoid body formation ...
Dec 20, 2024 · This in vitro study elucidated the effects of photobiomodulation (PBM) on the differentiation of immortalized adipose-derived stem cells (iADSCs) into NEBs.
[80]
Stem Cell and Synthetic Embryo Models: Advances, Applications ...
May 20, 2025 · Essential platforms for studying early developmental processes, embryoid bodies ... Holistic Recapitulation of Embryogenesis. Organoids are ...
[81]
https://doi.org/10.1038/s41563-020-00829-9
[82]
https://doi.org/10.1242/dev.201386
[83]
https://doi.org/10.1038/s41586-021-04267-8
[84]
https://doi.org/10.1038/s41556-022-00984-y
[85]
https://doi.org/10.1016/j.cell.2022.07.028
[86]
https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(22)00497-0